

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Levamisole (6.5%) / Oxclozanide (13%) Formulation

Other means of identification : COOPERS NILZAN LV ORAL DRENCH (36089)

#### Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue  
Rahway, New Jersey U.S.A. 07065

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### 2. HAZARDS IDENTIFICATION

#### GHS Classification

Serious eye damage/eye irritation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - single exposure (Oral) : Category 2 (Central nervous system)

Specific target organ toxicity - repeated exposure : Category 2 (Brain, Liver)

Long-term (chronic) aquatic hazard : Category 2

#### GHS label elements

Hazard pictograms :



# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version 5.0      Revision Date: 2025/04/14      SDS Number: 10857722-00008      Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

Signal word	:	Danger
Hazard statements	:	H318 Causes serious eye damage. H361d Suspected of damaging the unborn child. H371 May cause damage to organs (Central nervous system) if swallowed. H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure. H411 Toxic to aquatic life with long lasting effects.
Precautionary statements	:	<p><b>Prevention:</b></p> <p>P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P260 Do not breathe mist or vapours. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P273 Avoid release to the environment. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.</p> <p><b>Response:</b></p> <p>P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor. P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor. P391 Collect spillage.</p> <p><b>Storage:</b></p> <p>P405 Store locked up.</p> <p><b>Disposal:</b></p> <p>P501 Dispose of contents/ container to an approved waste disposal plant.</p>
<b>Other hazards which do not result in classification</b>		
None known.		

---

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
oxyclozanide	2277-92-1	>= 10 -< 25
Silicic acid, aluminum salt	1335-30-4	>= 3 -< 10
levamisole hydrochloride	16595-80-5	>= 3 -< 10
Citric acid	77-92-9	< 10

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

### 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. If easy to do, remove contact lens, if worn. Get medical attention immediately.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water. Never give anything by mouth to an unconscious person.
Most important symptoms and effects, both acute and delayed	: Causes serious eye damage. Suspected of damaging the unborn child. May cause damage to organs if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

---

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides Chlorine compounds Nitrogen oxides (NO <sub>x</sub> )

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0	Revision Date: 2025/04/14	SDS Number: 10857722-00008	Date of last issue: 2024/07/06 Date of first issue: 2022/09/29
----------------	------------------------------	-------------------------------	---

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

## 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

## 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Do not get in eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

	practice, based on the results of the workplace exposure assessment
	Keep container tightly closed.
	Do not eat, drink or smoke when using this product.
	Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage	: Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.
Materials to avoid	: Do not store with the following product types: Strong oxidizing agents

## 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
oxyclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
Silicic acid, aluminum salt	1335-30-4	NAB	2 mg/m <sup>3</sup> (Aluminium)	ID OEL
	Further information: Not classified as carcinogenic to humans. Not enough data to classify these materials as carcinogenic to humans or animals			
levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal

Engineering measures	: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.
----------------------	--

### Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Particulates type

Hand protection

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

Material	: Chemical-resistant gloves
Remarks Eye protection	: Consider double gloving. : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

## 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: suspension
Colour	: yellow
Odour	: No data available
Odour Threshold	: No data available
pH	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

---

## 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

## 11. TOXICOLOGICAL INFORMATION

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg  
Method: Calculation method

**Components:****oxyclozanide:**

Acute oral toxicity : LD50 (Rat): 3,519 mg/kg  
Target Organs: Central nervous system

Acute toxicity (other routes of administration) : LDLo (sheep): 10 mg/kg  
Application Route: Intravenous

**Silicic acid, aluminum salt:**

Acute oral toxicity : LD50 (Rat, female): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity

Acute dermal toxicity : LD50 (Rabbit): > 5,000 mg/kg  
Remarks: Based on data from similar materials

**levamisole hydrochloride:**

Acute oral toxicity : LD50 (Rat): 180 mg/kg  
LD50 (Mouse): 223 mg/kg  
LD50 (Rabbit): 458 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

**Citric acid:**

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29**Skin corrosion/irritation**

Not classified based on available information.

**Components:****oxyclozanide:**

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

**Silicic acid, aluminum salt:**

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation
Remarks	:	Based on data from similar materials

**levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

**Citric acid:**

Species	:	Rabbit
Method	:	OECD Test Guideline 404
Result	:	No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****oxyclozanide:**

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

**Silicic acid, aluminum salt:**

Species	:	Chicken eye
Method	:	Chorioallantoic membrane vascularization assay
Result	:	Irreversible effects on the eye

**levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

**Citric acid:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

**Respiratory sensitisation**

Not classified based on available information.

**Components:****oxyclozanide:**

Exposure routes	:	Dermal
Remarks	:	Not classified due to lack of data.

**Silicic acid, aluminum salt:**

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse
Method	:	OECD Test Guideline 429
Result	:	negative

**levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****oxyclozanide:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
		Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
		Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
		Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**

Version 5.0      Revision Date: 2025/04/14      SDS Number: 10857722-00008      Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

**Germ cell mutagenicity - Assessment** : Weight of evidence does not support classification as a germ cell mutagen.

**Silicic acid, aluminum salt:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative  
Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**levamisole hydrochloride:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

**Citric acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: in vitro micronucleus test  
Result: positive

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Carcinogenicity**

Not classified based on available information.

**Components:****oxyclozanide:**

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29**Remarks** : Not classified due to lack of data.**Silicic acid, aluminum salt:**

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	104 weeks
Result	:	negative
Remarks	:	Based on data from similar materials

**levamisole hydrochloride:**

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	80 mg/kg body weight
Remarks	:	No significant adverse effects were reported

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
NOAEL	:	40 mg/kg body weight
Remarks	:	No significant adverse effects were reported

**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****oxyclozanide:**

Effects on fertility	: Test Type: Two-generation reproduction toxicity study Species: Rat, male and female Application Route: Oral General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development Result: No effects on fertility
	: Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: LOAEL: 75 - 100 mg/kg body

**Levamisole (6.5%) / Oxclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development : Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: LOAEL: 100 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: 32 mg/kg body weight  
Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

**Silicic acid, aluminum salt:**

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**levamisole hydrochloride:**

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Result: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity

## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version 5.0	Revision Date: 2025/04/14	SDS Number: 10857722-00008	Date of last issue: 2024/07/06 Date of first issue: 2022/09/29
----------------	------------------------------	-------------------------------	---

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

### Citric acid:

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

### STOT - single exposure

May cause damage to organs (Central nervous system) if swallowed.

### Components:

#### oxyclozanide:

Exposure routes : Oral  
Target Organs : Central nervous system  
Assessment : May cause damage to organs.

#### Citric acid:

Assessment : May cause respiratory irritation.

### STOT - repeated exposure

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.

### Components:

#### oxyclozanide:

Target Organs : Brain, Liver  
Assessment : May cause damage to organs through prolonged or repeated exposure.

#### levamisole hydrochloride:

Target Organs : Blood, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**

Version 5.0      Revision Date: 2025/04/14      SDS Number: 10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

**Repeated dose toxicity****Components:****oxyclozanide:**

Species	:	Rat
NOAEL	:	9 mg/kg
LOAEL	:	44.5 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver, spleen, Adrenal gland
Symptoms	:	Liver effects
Species	:	Dog
NOAEL	:	5 mg/kg
LOAEL	:	25 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months
Target Organs	:	Brain, Liver
Symptoms	:	blood effects, alteration in liver enzymes

**Silicic acid, aluminum salt:**

Species	:	Rat
NOAEL	:	> 100 mg/kg
Application Route	:	Ingestion
Exposure time	:	104 Weeks
Remarks	:	Based on data from similar materials

**levamisole hydrochloride:**

Species	:	Rat
NOAEL	:	2.5 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Testis
Species	:	Dog
LOAEL	:	20 mg/kg
Application Route	:	Oral
Exposure time	:	18 Months
Target Organs	:	Blood
Species	:	Dog
LOAEL	:	40 mg/kg
Application Route	:	Oral
Exposure time	:	3 Months

**Citric acid:**

Species	:	Rat
NOAEL	:	4,000 mg/kg

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

LOAEL	:	8,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	10 Days

### Aspiration toxicity

Not classified based on available information.

### Components:

#### **oxyclozanide:**

Not applicable

### Experience with human exposure

### Components:

#### **oxyclozanide:**

Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

#### **levamisole hydrochloride:**

Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

---

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

### Components:

#### **oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0.69 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

M-Factor (Acute aquatic toxicity) : 1

M-Factor (Chronic aquatic toxicity) : 1

#### **Silicic acid, aluminum salt:**

### Ecotoxicology Assessment

Chronic aquatic toxicity : No toxicity at the limit of solubility

#### **levamisole hydrochloride:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

## Levamisole (6.5%) / Oxyclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 64 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

### Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l  
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 1,535 mg/l  
Exposure time: 24 h

### Persistence and degradability

#### Components:

##### **oxyclozanide:**

Stability in water : Hydrolysis: 50 %(156 d)  
Method: OECD Test Guideline 111

##### **Citric acid:**

Biodegradability : Result: Readily biodegradable.  
Biodegradation: 97 %  
Exposure time: 28 d  
Method: OECD Test Guideline 301B

### Bioaccumulative potential

#### Components:

##### **oxyclozanide:**

Partition coefficient: n-octanol/water : log Pow: 3.99  
pH: 7  
Method: OECD Test Guideline 107

##### **Citric acid:**

Partition coefficient: n-octanol/water : log Pow: -1.72

### Mobility in soil

#### Components:

##### **oxyclozanide:**

Distribution among environmental compartments : log Koc: 4.83  
Method: OECD Test Guideline 106

### Other adverse effects

No data available

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxclozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

### 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxyclozanide)

Class : 9

Packing group : III

Labels : 9

Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3082

Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(oxyclozanide)

Class : 9

Packing group : III

Labels : Miscellaneous

Packing instruction (cargo aircraft) : 964

Packing instruction (passenger aircraft) : 964

Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3082

Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxyclozanide)

Class : 9

Packing group : III

Labels : 9

EmS Code : F-A, S-F

Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxy clozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

## 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

**Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.**

**Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health**

Hazardous substances that must be registered : Not applicable

**Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances**

Hazardous substances approved for use : Sodium hydroxide

Prohibited substances : Not applicable

Restricted substances : Not applicable

**Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials**

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 16. OTHER INFORMATION

Revision Date : 2025/04/14

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

**Levamisole (6.5%) / Oxyclozanide (13%) Formulation**Version  
5.0Revision Date:  
2025/04/14SDS Number:  
10857722-00008Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

**Full text of other abbreviations**

ID OEL : Indonesia. Occupational Exposure Limits

ID OEL / NAB : Long term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECL - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

# SAFETY DATA SHEET



## Levamisole (6.5%) / Oxy clozanide (13%) Formulation

Version  
5.0

Revision Date:  
2025/04/14

SDS Number:  
10857722-00008

Date of last issue: 2024/07/06  
Date of first issue: 2022/09/29

---

ID / EN